1. Summary of the Week
From July 11 to 17, a total of 21 agreements were signed worldwide. Within China’s biotech industry, there were two in-licensing deals, four out-licensing deals, and three domestic transactions.
In China, the largest out-licensing deal involved Dizal Pharma and AstraZeneca for the approved asset sunvozertinib, with an upfront payment of $600 million and a total deal value of $1.5 billion.
Globally, 12 deals were announced. Although none of the transactions disclosed major headline financial terms during this period, they reflect ongoing strategic partnership activity across the industry.
2026年7月11日-17日，全球医药市场共签署了21项资产授权和合作协议。中国市场共达成9项交易，包括2项引进交易、4项出海交易和3项国内交易。
国内市场上，本周最大的出海交易是迪哲医药与AstraZeneca就已获批资产sunvozertinib达成在全球范围内的独家授权许可协议，首付款6亿美元，总金额可达15亿美元。
国际市场上，本周共签署了12项资产授权和合作协议。就首付款而言，本周没有大型交易达成。
2. Licensing Deals
China Licensing and Cooperation Deals July 2026
| Deal Type | Licensor | Licensee | Assets | Disease | Stage | Total amount ($ million) |
Upfront ($ million) |
Deal Territory |
|---|---|---|---|---|---|---|---|---|
| China IL | AFT Pharmaceuticals | TongDe Pharmaceutical 通德药业 |
acetaminophen + ibuprofen | pain; fever | Approved | Undisclosed | Undisclosed | Chinese Mainland |
| China IL | Nevakar | Zhaoke Ophthalmology 兆科眼科 |
NVK-002 (atropine) | myopia | Filed | Undisclosed | Undisclosed | Global |
| China OL | Dizal Pharma 迪哲医药 |
AstraZeneca | sunvozertinib | non-small cell lung cancer (NSCLC); small lymphocytic lymphoma (SLL); mantle cell lymphoma (MCL); B-cell lymphoma; chronic lymphocytic leukemia (CLL); oncology; marginal zone lymphoma (MZL) | Approved | 1,500 | 600 | Global |
| China OL | Hansoh Pharmaceutical 翰森制药 |
Avere | HS-20118 (AVR-001) | plaque psoriasis; psoriasis | Phase II | 2,300 | 120 | United States; Europe; Japan; Other |
| China OL | Innovent Biologics 信达生物 |
Spero Therapeutics | IBI355 | systemic lupus erythematosus (SLE); Sjögren’s syndrome; autoimmune disease | Phase I | 1,100 | Undisclosed | United States; Europe; Japan; Other |
| China OL | Zhaoke Ophthalmology 兆科眼科 |
Nevakar | NVK-002 (atropine) | myopia | Filed | Undisclosed | Undisclosed | United States |
| China Domestic | Insilico Medicine 英矽智能 |
Bora 保瑞药业 |
drug innovation model combined with Pharma.AI technology | Undisclosed | Undisclosed | 2,500 | Undisclosed | Global |
| China Domestic | Insilico Medicine 英矽智能 |
China Medical System 康哲药业 |
AI-empowered drug discovery | Undisclosed | Pre-Clinical | Undisclosed | Undisclosed | Global |
| China Domestic | DPTechnology 深势科技 |
Excalipoint 艾科联 |
AI-enabled TCE development platform | Undisclosed | Undisclosed | Undisclosed | Undisclosed | Global |
2a. China Section
3. M&A Deals
M&A Deals July 2026
| Status | Acquiree | Acquiror | Acquisition Type | Item | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| Proposed | AtaiBeckley | Eli Lilly | Full Acquisition | HS-20118 (AVR-001) | 3,800 | 2,800 |
| Proposed | Avere | NextCure | Reverse Takeover | N,N-dimethyltryptamine; BPL-003 (intranasal 5-MeO-DMT, dry powder); midomafetamine | Undisclosed | Undisclosed |
4. Top Deals of 2026
Top China Out-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-01-30 | CSPC Pharma 石药集团 |
AstraZeneca | Endocrine & Metabolic | IND; Pre-Clinical | 18,500 | 1,200 |
| 2026-05-29 | Innovent Biologics 信达生物 |
Pfizer | Oncology | Pre-Clinical | 10,500 | 650 |
| 2026-01-13 | RemeGen 荣昌生物 |
AbbVie | Rare Disease; Oncology | Phase II | 5,600 | 650 |
| 2026-05-12 | Hengrui Pharmaceuticals 恒瑞医药 |
Bristol-Myers Squibb | Haematology; Oncology | Pre-Clinical | 15,200 | 600 |
| 2026-07-14 | Dizal Pharma 迪哲医药 |
AstraZeneca | Haematology; Oncology; Rare Diseases | Approved | 1,500 | 600 |
| 2026-02-08 | Innovent Biologics 信达生物 |
Eli Lilly | Immunology; Oncology | Pre-Clinical | 8,850 | 350 |
| 2026-07-08 | Chia Tai Tianqing Pharmaceutical 正大天晴 |
AstraZeneca | Respiratory | Phase III | 2,100 | 200 |
| 2026-02-02 | Sanegene Bio 圣因生物 |
Genentech Roche | Unknown/To be determined | Pre-Clinical | 1,700 | 200 |
| 2026-01-12 | SciNeuro Pharma 赛神医药 |
Novartis | Neurology | Pre-Clinical | 1,665 | 165 |
| 2026-03-04 | CTTQ Pharma 正大天晴 |
Sanofi | Hematology; Rare Disease; Immunology; Oncology | Approved | 1,530 | 135 |
Top China In-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-05-14 | AriBio | Fosun Pharmaceutical 复星医药 |
Neurology; Cardiovascular; Genitourinary | Approved | Undisclosed | 80 |
| 2026-04-17 | Aligos Therapeutics | Amoytop Biotech 特宝生物 |
Infection; Gastroenterology | Phase II | 445 | 25 |
| 2026-03-09 | Rapport Therapeutics | Tenacia Biotechnology 元羿生物 |
Neurology; Psychiatry | Phase II | 328 | 20 |
| 2026-07-03 | Adneuris Therapeutics | Conba Pharmaceutical 康恩贝 |
Anesthesiology; Musculoskeletal; Psychiatry; Oncology | Phase III | 111.5 | 17.5 |
| 2026-06-16 | Dimerix | Everest Medicines 云顶新耀 |
Infection; Genitourinary | Phase III | 340 | 10 |
Top China Domestic Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-05-29 | Genrix Bio 智翔金泰 |
YaoPharma 药友制药 |
Hematology; Rare Diseases; Immunology; Dermatology; Oncology | Filed | 253 | 42 |
| 2026-03-23 | Corxel Pharmaceuticals 箕星药业 |
Everest Medicines 云顶新耀 |
Cardiovascular | Approved | 50 | 30 |
| 2026-02-05 | Micot Technology 麦科奥特 |
Everest Medicines 云顶新耀 |
Genitourinary; Endocrine & Metabolic | Phase III | 172.48 | 27.82 |
| 2026-01-17 | Raynovent 众生药业 |
Qilu Pharmaceutical 齐鲁制药 |
Gastroenterology; Respiratory; Endocrine & Metabolic | Phase III | 139.10 | 27.82 |
| 2026-04-28 | Huahui Health 华辉安健 |
BeOne Medicines 百济神州 |
Oncology | Pre-Clinical | 2,024 | 20 |
| 2026-01-12 | Wan Bang De 万邦德 |
Hisoar Pharmaceutical 海翔药业 |
Neurology; Rare Disease | Pre-Clinical | 20.87 | 16.69 |
| 2026-01-06 | Accendatech 尚德药缘 |
Yifan Pharmaceutical 亿帆医药 |
Neurology; Ophthalmology; Respiratory; Hematology; Rare Disease; Immunology; Oncology | Phase III | 20.87 | 13.91 |
| 2026-02-04 | Akeso Biopharma; Kangrong Dongfang 康方生物 |
Jumpcan Pharmaceutical 济川药业 |
Rare Disease; Cardiovascular | Approved | 12.52 | 11.13 |
| 2026-01-20 | Insilico Medicine 英矽智能 |
Hengtai Biotechnology 衡泰生物 |
Neurology | Pre-Clinical | 66 | 10 |
| 2026-07-04 | EnliTISA 艾缇亚 |
Hisun Pharmaceutical 海正药业 |
Gastroenterology; Respiratory; Oncology; Rare Diseases | Phase II | 62 | 6.3 |
Top Global Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-03-20 | Synnovation Therapeutics | Novartis | Oncology | Phase I/II | 3,000 | 2,000 |
| 2026-06-01 | Edgewise Therapeutics | Servier | Musculoskeletal; Rare Diseases | Phase II | 2,650 | 1,550 |
| 2026-06-08 | Nurix Therapeutics | Roche | Haematology; Rare Diseases; Immunology; Oncology | Phase III | 2,300 | 700 |
| 2026-03-19 | Corium Therapeutics | Collegium Pharmaceutical | Psychiatry | Approved | 785 | 650 |
| 2026-03-09 | GSK | Alfasigma | Gastroenterology; Rare Disease; Dermatology; Endocrine & Metabolic | Filed | 690 | 300 |
| 2026-02-23 | Vir Biotechnology | Astellas Pharma | Oncology | Phase I/II | 1,705 | 240 |
| 2026-03-23 | Kali Therapeutics | Sanofi | Musculoskeletal; Immunology | Phase I | 1,230 | 180 |
| 2026-05-19 | Hansa Biopharma | Serb Sa | Neurology; Rare Diseases; Musculoskeletal; Hematology; Immunology; Endocrinology & Metabolism | Approved | 130 | 124 |
| 2026-06-24 | Antares Therapeutics | Novartis | Oncology | Undisclosed | 1,905 | 105 |
| 2026-02-18 | CSL | Eli Lilly | Respiratory; Gastroenterology; Infection; Rare Disease; Musculoskeletal; Immunology; Cardiovascular; Oncology; Genitourinary; Endocrine & Metabolic | Phase III | 100 |
5. 2021-2025 China Innovative Drug Licensing Transactions
BioToChina.org 